The risks of risk aversion in drug regulation

Nature Reviews Drug Discovery

Volumn 12, Issue 12, 2013, Pages 907-916

  Eichler, Hans Georg ^a   Bloechl Daum, Brigitte ^b   Brasseur, Daniel ^c   Breckenridge, Alasdair ^d   Leufkens, Hubert ^e   Raine, June ^d   Salmonson, Tomas ^f   Schneider, Christian K ^g   Rasi, Guido ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Federal Agency for Medicines and Health Products Belgium   (Belgium)

^d MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^e MEDICINES EVALUATION BOARD   (Netherlands)

^f MEDICAL PRODUCTS AGENCY   (Sweden)

^g Danish Health and Medicines Authority   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; NATALIZUMAB; NEUROLEPTIC AGENT; TOLCAPONE;

ADVERSE DRUG REACTION; CARDIOTOXICITY; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG CONTROL; DRUG SURVEILLANCE PROGRAM; ERROR; HEART DEATH; HUMAN; LICENSING; MEDICAL SOCIETY; PATIENT ADVOCACY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION;

ANIMALS; DRUG AND NARCOTIC CONTROL; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 84889574642     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4129     Document Type: Review

References (85)

1. European Medicines Agency (EMA). Benefit-risk methodology project. Work package 1 report: Description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network. EMA website [online], http://www.ema.europa.eu/docs/en-GB/document- library/Report/2011/07/ WC500109478.pdf (2011
2. Beckman, R. A., Clark, J. & Chen, C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Rev. Drug Discov. 10, 735-748 (2011
3. Manski, C. Adaptive partial drug approval: A health policy proposal. Economists' Voice 6, 1-5 (2009
4. Commission of the European Communities. Communication from the commission on the precautionary principle. EC website [online], http://ec.europa.eu/dgs/ health-consumer/library/ pub/pub07-en.pdf (2000
5. Wiener, J. B. Whose precaution after all? A comment on the comparison and evolution of risk regulatory systems. Duke Journal Comparative International Law 13, 207 (2003
6. The European Risk Forum (ERF). The ERF study. The precautionary principle application and way forward. ERF website [online], http://www.riskforum. eu/pdf/2011/ERF%20Study%20The%20 Precautionary%20Principle-%20Application%20 and%20Way%20Forward.pdf (2011
7. Gezondheidsraad (Health Council of the Netherlands). Advice: Prudent precaution. Gezondheidsraad website [online], http://www.gezondheidsraad.nl/ sites/default/ files/200818E-0.pdf (2008
8. Lenert, L. A., Markowitz, D. R. & Blaschke, T. F. Primum non nocere? Valuing of the risk of drug toxicity in therapeutic decision making. Clin. Pharmacol. Ther. 53, 285-291 (1993
9. Lofstedt, R. E. Risk versus hazard - how to regulate in the 21st century. Eur. J. Risk Regulation 2, 149-168 (2011
10. Graham, J. D. & Wiener, J. B. Risk vs. Risk: Tradeoffs in Protecting Health and the Environment 1-352 (Harvard Univ. Press, 1995
11. McNeil, B. J., Pauker, S. G., Sox, H. C. Jr & Tversky, A. On the elicitation of preferences for alternative therapies. N. Engl. J. Med. 306, 1259-1262 (1982
12. Johnson, F. R. et al. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J. Manag. Care Pharm. 16, 616-628 (2010
13. Poland, G. A. & Jacobson, R. M. The age-old struggle against the antivaccinationists. N. Engl. J. Med. 364, 97-99 (2011
14. European Medicines Agency (EMA). Benefit-risk methodology project. Report on risk perception study module. EMA website [online], http://www.ema. europa.eu/docs/en-GB/document-library/Report/ 2012/02/WC500123226.pdf (2012
15. Bouvy, J. C. The Evaluation of Drug Regulation. Economic Approaches into the Valuation and Evaluation of the Drug Regulatory Framework. Thesis, Utrecht Univ. and Erasmus Univ. Rotterdam (2013
16. Arnardottir, H. Regulatory Benefit-Risk Assessment. Different Perspectives. Thesis, Univ. Medical Center Groningen (2013
17. Arnott, J. et al.Enhancing communication about paediatric medicines: Lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reaction. PLoS ONE 7, e46022 (2012
18. Carpenter, D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. 1-824 (Princeton Univ. Press, 2010
19. Thun-Hohenstein, E. Who's afraid of a cure for cancer? Ukraine Drug Net website [online], http://www.ukrain-drug.net/papers/book/patient.htm (2004
20. Moore, T. J. & Furberg, C. D. The safety risks of innovation. The FDA's Expedited Drug Development pathway. JAMA 308, 869-870 (2012
21. Eichler, H. G. et al. Bridging the efficacy-effectiveness gap: A regulator's perspective on addressing variability of drug response. Nature Rev. Drug Discov. 10, 495-506 (2011
22. European Medicines Agency (EMA). Assessment report. Forxiga (dapagliflozin). Procedure No.: EMEA/H/C/002322. EMA webite [online], http://www. ema.europa.eu/docs/en-GB/document-library/ EPAR-Public-assessment- report/human/002322/ WC500136024.pdf (2012
23. Dodd, C. N. et al. International collaboration to assess the risk of Guillain Barré syndrome following influenza A (H1N1) 2009 monovalent vaccines. Vaccine 31, 4448-4458 (2013
24. Warren, J. B., Day, S. & Feldschreiber, P. Symmetrical analysis of risk-benefit. Br. J. Clin. Pharmacol. 74, 757-761 (2012
25. Bouvy, J. C., Koopmanschap, M. A., Shah, R. R. & Schellekens, H. The cost-effectiveness of drug regulation: The example of thorough QT/QTc studies. Clin. Pharmacol. Ther. 91, 281-288 (2012
26. Bouvy, J. C., Ebbers, H. C., Schellekens, H. & Koopmanschap, M. A. The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin. Pharmacol. Ther. 93, 433-442 (2013
27. The Academy of Medical Sciences (UK). A new pathway for the regulation and governance of health research, 2011. The Academy of Sciences website [online], http://www.acmedsci.ac.uk/download. php?file=/images/project/ 130734957423.pdf (2011
28. Duley, L. et al. Specific barriers to the conduct of randomized trials. Clin. Trials 5, 40-48 (2008
29. Kramer, J. M., Smith, P. B. & Califf, R. M. Impediments to clinical research in the United States. Clin. Pharmacol. Ther. 91, 535-541 (2012
30. Arrowsmith, J. Trial watch: Phase II failures: 2008-2010. Nature Rev. Drug Discov. 10, 328-329 (2011
31. Fernandez, J. M., Stein, R. M. & Lo, A. W. Commercializing biomedical research through securitization techniques. Nature Biotech. 30, 964-975 (2012
32. Roy, A. S. A. Stifling new cures: The true cost of lengthy clinical drug trials. Manhattan Institute website [online], http://www.manhattan-institute. org/ pdf/fda-05.pdf (2012
33. The Infectious Diseases Society of America (IDSA). Limited population antibacterial drug (lPAD) legislation would expedite development of much-needed antibiotics. IDSA website [online], http://www.idsociety.org/2012-LPAD-Proposal- Backing/ (2012
34. Karres, J. & Tomasi, P. New medicines for type II diabetes in adolescents: Many products, few patients. Expert Rev. Clin. Pharmacol. 6, 227-229 (2013
35. Klein, R. M. FDA's latest efforts in patient-focused drug development.* now in full swing! US FDA website [online], http://blogs.fda.gov/fdavoice/ index.php/2013/06/fdas-latest-efforts-in%20 patient focused-drug-development-now%20in%20 full swing/ (2013
36. European Medicines Agency (EMA). The role of patients as members of the EMA Human Scientific Committees. EMA website [online], http://www.ema. europa.eu/docs/en-GB/document-library/ Other/2011/12/WC500119614.pdf (2011
37. European Medicines Agency (EMA). Outcome report on pilot phase for participation of patient representatives in Scientific Advisory Group (SAG) meetings. EMA website [online], http://www.ema. europa.eu/docs/en-GB/document- library/ Report/2011/12/WC500119201.pdf (2011
38. Johnson, F. R. et al. Multiple sclerosis patients' benefit-risk preferences: Serious adverse event risks versus treatment efficacy. J. Neurol. 256, 554-562 (2009
39. Eichler, H. G., Abadie, E., Baker, M. & Rasi, G. Fifty years after thalidomide; what role for regulators? Br. J. Clin. Pharmacol. 74, 731-733 (2012
40. Slovic, P. Trust, emotion, sex, politics, and science: Surveying the risk-assessment battlefield. Risk Anal. 19, 689-701 (1999
41. Kahneman, D. Thinking, Fast and Slow 1- 512 (Penguin, 2011
42. Zineh, I. & Woodcock, J. Clinical pharmacology and the catalysis of regulatory science: Opportunities for the advancement of drug development and evaluation. Clin. Pharmacol. Ther. 93, 515-525 (2013
43. Guo, J. J. et al. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health 13, 657-666 (2010
44. European Medicines Agency (EMA). Benefit-risk methodology project. Work package 3 report: Field tests. EMA website [online], http://www.ema.europa. eu/docs/en-GB/document-library/Report/2011/09/ WC500112088.pdf (2011
45. Protect Consortium. Review of methodologies for benefit and risk assessment of medication. PROTECT website [online], http://www.imi-protect.eu/ documents/ShahruletalReviewofmethodologiesfor benefitandriskassessmentofmedicationMay2013.pdf (2013
46. Bouder, F., Slavin, D. & Löfstedt, R. The Tolerability of Risk. A New Framework for Risk Management 1-160 (Earthscan, 2007
47. Bandle, T. in The Tolerability of Risk. A New Framework for Risk Management Ch.5 (eds Bouder, F., Slavin, D. & Löfstedt, R.) 93-104 (Earthscan, 2007
48. European Commission. Improvement of risk assessment in view of the needs of risk managers and policy makers. EC website [online], http://ec.europa.eu/ health/scientific-committees/environmental-risks/ docs/scher-o-154.pdf (2011
49. US Food and Drug Administration (FDA). Guidance for industry. Diabetes mellitus - Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. FDA website [online], http://www.fda.gov/downloads/Drugs/ Guidance ComplianceRegulatoryInformation/Guidance s/ ucm071627.pdf (2008
50. Vesikari, T. et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354, 23-33 (2006
51. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control. Clin. Trials 19, 61-109 (1998
52. European Medicines Agency (EMA). ICH guideline E2C (R2) on periodic benefit-risk evaluation report (PBRER). EMA website [online], http://www.ema. europa.eu/docs/en-GB/document-library/Regulatory- and-procedural-guideline/2012/ 12/WC500136402. pdf (2013
53. Institute of Medicine of the National Academies. Report: Ethical And Scientific Issues In Studying The Safety Of Approved Drugs. 1-292 (National Academies, 2012
54. Chowdhury, B. A. & Dal Pan, G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N. Engl. J. Med. 362, 1169-1171 (2010
55. Woodcock, J., Khan, M. & Yu, L. X. Withdrawal of generic budeprion for nonbioequivalence. N. Engl. J. Med. 367, 2463-2465 (2012
56. Southworth, M. R., Reichman, M. E. & Unger, E. F. Dabigatran and postmarketing reports of bleeding. N. Engl. J. Med. 368, 1272-1274 (2013
57. European Medicines Agency (EMA). Concept paper on extrapolation of efficacy and safety in medicine development. Draft. EMA website [online], http://www. ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/ 2012/06/WC500129285.pdf (2012
58. Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360-364 (2004
59. BBC. GlaxoSmithKline to pay $3bn in US drug fraud scandal. BBC website [online], http://www.bbc.co.uk/ news/world-us-canada 18673220 (2012
60. Thomas, K. Health groups criticize allergy drug promotion. NY Times website [online], http://www. nytimes.com/2012/06/21/health/health-advocates- denounce-mercks-claritin-marketing.html (2012
61. Applbaum, K. Is marketing the enemy of pharmaceutical innovation? Hastings Center Report 39, 13-17 (2009
62. Adams, B. EMA under fire from European Parliament. Pharmafile website [online], http://www.pharmafile. com/news/156464/ema-under-fire-european- parliament (2011
63. Mullard, A. Mediator scandal rocks French medical community. Lancet 377, 890-892 (2011
64. Thepharmaletter. US public confidence in the FDA plunges, new drug oversight a priority, survey finds. Thepharmaletter website [online], http://www. thepharmaletter.com/file/9923/us-public-confidence-in-the-fda- plunges-new-drug-oversight-a-priority-survey-finds.html (2008
65. Health Canada. The regulatory roadmap for health products and food. Health Canada website [online], http://www.hc-sc.gc.ca/ahc-asc/alt-formats/pdf/ activit/mod/roadmap-feuillederoute-eng.pdf (2012
66. US Food and Drug Administration (FDA). FDA transparency initiative. FDA website [online], http://www.fda.gov/AboutFDA/Transparency/ TransparencyInitiative/default.htm (2012
67. European Medicines Agency (EMA). Special topics. Transparency. EMA website [online], http://www.ema. europa.eu/ema/index.jsp?curl=pages/special- topics/general/general-content-000526.jsp&mid= WC0b01ac0580050108 (2013
68. European Medicines Agency (EMA). European Medicines Agency releases for public consultation its draft policy on the publication and access to clinical-trial data. EMA website [online], http://www.ema. europa.eu/ema/index. jsp?curl=pages/news-and- events/news/2013/06/news-detail-001825. jsp&mid=WC0b01ac058004d5c1 (2013
69. Kang, P. The Tysabri game plan. Forbes website [online], http://www.forbes.com/2006/03/08/tysabri-elan-biogen cx-pk-0308tysabri.html (2006
70. Calfee, J. A Representative Survey of M. S. Patients on Attitudes Towards the Benefits and Risks of Drug Therapy. 1-29 (AEI-Brookings Joint Center for Regulatory Studies, 2006
71. Miller, C. E., Karpinski, M. & Jezewski, M. A. Relapsing-remitting multiple sclerosis patients' experience with natalizumab. Int. J. MS Care14, 39-44 (2012
72. Vinhas de Souza, M. et al. Drug-induced PML: A global agenda for a global challenge. Clin. Pharmacol. Ther. 91, 747-750 (2012
73. European Medicines Agency (EMA). Tysabri: EPAR - product information. EMA website [online], http:// www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000603/ WC500044686.pdf (2013
74. US Food and Drug Administration (FDA). Lotronex (alosetron hydrochloride) information. FDA website [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsand Providers/ucm110450.htm (2012
75. US Food and Drug Administration (FDA). Questions and answers about lotronex (6/7/2002). FDA website [online], http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm110859. htm#whynotIND (2013
76. Chang, L. et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data. Am. J. Gastroenterol. 101, 1069-1079 (2006
77. Chang, L., Tong, K. & Ameen, V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: Clinical characteristics, outcomes, and incidences. Am. J. Gastroenterol. 105, 866-875 (2010
78. US Food and Drug Administration (FDA). Proposal to withdraw approval for the breast cancer indication for bevacizumab (avastin). June 28, 2011. A matter of record (301) 890-4188. FDA website [online], http://www.fda.gov/downloads/ NewsEvents/ MeetingsConferencesWorkshops/UCM261614.pdf (2011
79. US Food and Drug Administration (FDA). Proposal to withdraw approval for the breast cancer indication for avastin (bevacizumab). Decision of the Commissioner. FDA website [online], http://www.fda.gov/downloads/ NewsEvents/Newsroom/UCM280546.pdf (2011
80. Manganiello,M. & Anderson, M. Back to Basics. HIV/ AIDS advocacy as a model for catalyzing change. HCM Strategists website [online], http://www.hcmstrategists. com/content/Back2Basics-HIV-AIDSAdvocacy.pdf (2011
81. Weber, B. Spencer Cox, AIDS activist, dies at 44. NYTimes website [online], http://www.nytimes. com/2012/12/21/nyregion/spencer-cox-aids-activist- dies-at 44.html (2012
82. European Organisation for Rare Diseases (EURORDIS). Activity report 2012 & workplan 2013. EURORDIS website [online], http://www.eurordis.org/sites/ default/ files/activity-report 2012.pdf (2012
83. European Organisation for Rare Diseases (EURORDIS). "Medicines for children: Better, more and faster". EURORDIS position paper on the proposal for a regulation on medicinal products for paediatric use. EURORDIS website [online], http://www.eurordis.org/IMG/pdf/eurordis- position-medicines-children- 31jan05.pdf (2005
84. Contact Group Myeloma and Waldenstrom Patients (CMWP). European Symposium Myeloma Waldenström 2008. Final report. CMWP website [online], http://www.cmwp.nl/~uploads/interactionBlock2/ Final-report-Symposium- maastricht.pdf (2008
85. Wicks, P., Vaughan, T. E., Massagli, M. P. & Heywood, J. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nature Biotech. 29, 411-414 (2011